尤瑞克林联合奥扎格雷钠治疗老年缺血性脑卒中患者的临床观察

The Clinical Observation of Elderly Patients With Ischemic Stroke Using The Urinary Kallidinogenase Combined Ozagrel Sodium

目的观察注射用尤瑞克林联合奥扎格雷钠在老年缺血性脑卒中治疗过程中的安全性和疗效。方法本研究选取住院且年龄在60岁以上确诊为缺血性脑卒中患者,在发病6 h^7 d内接受治疗。入院后根据NIHSS卒中量表评分后,分为轻度、中度、重度三组。且随机分入治疗组及对照组。对照组患者静点250 ml生理盐水加注射用奥扎格雷钠80 mg,每日2次静滴,疗程为14 d,治疗组在应用奥扎格雷钠基础上加用注射用尤瑞克林0.15 PNA加入150 ml生理盐水中静滴,疗程为14 d。各组在治疗过程中均可以根据病情给予脱水剂、降压药等治疗。每组均在治疗前,治疗后7天,14天及21天应用NIHSS评分进行记录评分。结果尤瑞克林组治疗后与治疗前的NIHSS评分比较差异有统计学意义(P<0.01),与奥扎格雷组对比改善程度差异具有统计学意义。结论尤瑞克林联合奥扎格雷钠可以有效并且较安全的改善老年缺血性脑卒中患者的神经功能缺损症状。

Objective To observe the efficacy and safety during the treatment of senile ischemic stroke by using the injection of urinary kallidinogenase joint ozagrel sodium. Methods The study concerned with hospitalized patients diagnosed with ischemic strokes whose age are over 60 years old and get treated within 6 hours to 7 days after the stroke. Divide the patients into mild, moderate and severe groups according to NIHSS. The patients would be randomly divided into treatment group and control group. The control group will be given intravenous infusion of 80 mg ozagrel added into 250 ml saline, twice a day, for 14 days. The treatment group will be given intravenous infusion of 0.15 PNA of urinary kallidinogenase on the basis of 80 mg ozagrel added into 150 ml saline. The treatment is lasts for 14 days. The three groups will be assessed by NIHSS before the treatment and 7 days, 14 days, and 21 days. Results The comparison of NIHSS assessment of urinary kallidinogenase group before and after the treatment was statistical signifcant （P 〈 0.01）, and there were signifcant differences in ozagrel group improve the contrast degree. Conclusion The injection of urinary kallidinogenase joint ozagrel sodium can be used as an effective and safe improved treatment of treating neurological defcit symptoms of patients with ischemic stroke.